AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

NextEdge Admin

18 Dec 2024

2 min 40 sec

Roche has announced that its cobas® Mass Spec solution, including the cobas® i 601 analyzer and the first Ionify® reagent pack for steroid hormone assays, has received CE mark approval. This marks a significant step in the global rollout of the cobas Mass Spec solution, which aims to bring automated, integrated, and standardized clinical mass spectrometry testing to routine laboratories worldwide. The solution will initially offer over 60 analytes for steroid hormone testing, vitamin D metabolites, immunosuppressant drugs, therapeutic drug monitoring (TDM), and drugs of abuse testing (DAT).

The cobas Mass Spec solution is designed to revolutionize clinical diagnostics by making high-sensitivity, high-specificity mass spectrometry more accessible. According to Matt Sause, CEO of Roche Diagnostics, it has the potential to significantly improve patient care. For instance, in breast cancer patients undergoing hormone therapy, the solution can help detect early therapeutic response changes, enabling timely treatment adjustments.

Mass spectrometry is widely regarded as the diagnostic gold standard for various clinical applications, including endocrinology, vitamin D testing, and monitoring immunosuppressant and therapeutic drug levels. It provides clear, accurate results, which enable healthcare providers to make more informed, timely decisions for patients, such as optimizing antibiotic use and monitoring disease progression.

Roche’s proprietary chemistry technology has made it possible to automate mass spectrometry, addressing the challenges of low automation, high complexity, and variability that have previously limited its use to specialized labs. The cobas Mass Spec solution integrates seamlessly into Roche’s cobas® pro platform, supporting clinical chemistry, immunochemistry testing, and lab automation. This integration enhances workflow efficiency and environmental sustainability, bringing mass spectrometry to a wider range of clinical settings.